Visen Pharmaceuticals 2024 AR2
The report highlights Visen Pharmaceuticals' operational and ESG achievements for the fiscal year 2024. During the year, the company successfully submitted the Biologics License Application (BLA) for its core product, lonapegsomatropin, which was accepted by the NMPA. Additionally, Visen completed key clinical milestones for its pipeline candidates, palopegteriparatide and navepegritide. On the sustainability front, the company established a three-tier ESG governance framework, conducted its first materiality assessment, and actively supported patient advocacy programs for achondroplasia and hypoparathyroidism.
Company: Visen Pharmaceuticals
Sector: Health Care
Country: China
Year: 2024
Type: AR2
Pages: 194
Visen Pharmaceuticals
Annual Report
The report highlights Visen Pharmaceuticals' operational and ESG achievements for the fiscal year 2024. During the year, the company successfully submitted the Biologics License Application (BLA) for its core product, lonapegsomatropin, which was accepted by the NMPA. Additionally, Visen completed key clinical milestones for its pipeline candidates, palopegteriparatide and navepegritide. On the sustainability front, the company established a three-tier ESG governance framework, conducted its first materiality assessment, and actively supported patient advocacy programs for achondroplasia and hypoparathyroidism.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees